Medical News Today16d
Rexulti and cost
Rexulti tablets are available in strengths of 0.25 milligrams (mg), 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg. The cost per month for Rexulti with insurance could also depend on your plan. For example ...
Indiatimes29d
Alembic Pharmaceuticals gets USFDA nod for generic antidepressant tablets
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti tablets of 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg, of Otsuka Pharmaceutical Company, Ltd, it ...
Business Standard29d
Alembic Pharmaceuticals receives USFDA approval for Brexpiprazole Tablets
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg, of Otsuka Pharmaceutical Company, Ltd. (Otsuka) ...
H. Lundbeck A/S: Lundbeck reached record revenue of DKK 22 billion in 2024 with accelerated growth for strategic brands (+21% CER)
Key highlights Lundbeck's total revenue grew by +14% CER[1] (+11% DKK) to DKK 22,004 million in 2024, with all regions contributing to growth United States: DKK 11,325 million (+16% CER; +15% DKK) Eur ...
Daily29d
Alembic Pharma bags USFDA final approval for schizophrenia drug Brexpiprazole
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg, of Otsuka Pharmaceutical Company, Ltd.
Yahoo Finance27d
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo, all administered once weekly. The trial included 1,407 ...
appliedclinicaltrialsonline28d
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its ...
BioSpace25d
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo, all administered once weekly. The trial included 1,407 ...
Drug Store News24d
FDA approves Alembic’s generic Rexulti
Alembic has received permission from the Food and Drug Administration for brexpiprazole tablets, which is the generic of Otsuka’s Rexulti. Brexpiprazole is an atypical antipsychotic used as an ...
FierceBiotech1d
AnaptysBio's PD-1 drug reduces rheumatoid arthritis in phase 2 trial
AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...
Healthline14d
Rexulti Interactions: Alcohol, Medications, and Others
Rexulti (brexpiprazole) has potential interactions with alcohol and other medications. For example, Rexulti can interact with other antipsychotics, such as risperidone (Risperdal). An interaction ...
The American Journal of Managed Care1d
Risdiplam Tablet for Spinal Muscular Atrophy Receives FDA Approval
The 5 mg risdiplam tablet provides the same efficacy and safety for spinal muscular atrophy as the currently available oral ...